PubMed Health⌕ Search

Biomedical subjects

B Chalchat

Publications and source records attributed to B Chalchat.

4 recordsLinked to original sources
PubMed2002

[Doping in high-level athletes].

Recent doping affairs clearly demonstrate that all sports are concerned, leading to a generalized suspicion concerning champions and their performance. Many athletes struggling to reach their own personal goals have the unacceptable impression that they cannot compete fairly with competitors who are presumably (or effectively) doped. This situation may easily lead to deviant behavior. The sincerity of many high-level athletes when they discuss doping is very questionable in light of the notoriety and financial aspect linked with success. Public image is all important.Unfortunately, at this level is appears to be utopic to assume preventive measures would be effective. Several factors are involved Taking into consideration these different elements, one could be rather pessimistic concerning the eradication of doping in high-level athletes. There could even be a risk of seeing a trend towards public acceptance of more or less "tolerated" doping among professional athletes, similar to what is observed in the United States. It might be preferable to concentrate efforts on education and prevention in the young population.

Doping in Sports↗
PubMed1993

[Current challenges for the pharmaceutical research industry].

The Research Pharmaceutical Industry is currently facing a number of increasingly complex challenges. Today indeed, the discovery and marketing of innovative medicines is linked: not only to Compagnies' abilities to solve relatively basic and traditional difficulties which have deeply changed over the past few years, for instance: the regulatory constraints, the dramatic increase in development costs, the critical mass required for investments, the development time periods and the protection of innovation, human resources and organization; but also to the acceptance of recent factors which the Research Pharmaceutical Industry must imperatively overcome, such as: the new Research channels and namely biotechnologies, the building of a pharmaceutical Europe and the internationalization of molecules, the needs of the third world, the innovation financing and the control of Health expenditures, the public opinion's shift in expectations regarding ethical and environmental issues. The Pharmaceutical Industry is currently in a shake-up phase during which it will undergo deep changes, with regard both to its activities and in relations with its environment.

Drug Costs↗